 CAMBRIDGE, Mass.--BUSINESS WIRE--- SAGE Sage--Today, Sage Therapeutics, Inc. NASDAQ: SAGE, a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, reported business highlights and financial results for the fourth quarter and full year ended December 31, 2020. Although 2020 was a challenging year, Sages commitment to rigorous science, innovation and disciplined execution resulted in significant pro 